Cough syrup contaminated with DEG has caused ARI and the death of many children in The Gambia.

Published Date: 06 Mar 2023

USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...

Read Full News

Latest News

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Advanced CKM Stages Linked to Mortality and Liver Fibrosis in MASLD

Advanced CKM Stages Linked to Mortality and Liver Fibrosis in MASLD

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

Bariatric Surgery Type Impacts Survival for Older Patients with ESKD

Bariatric Surgery Type Impacts Survival for Older Patients with ESKD

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

Todays Updates

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Todays Updates

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Latest News

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Advanced CKM Stages Linked to Mortality and Liver Fibrosis in MASLD

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

Bariatric Surgery Type Impacts Survival for Older Patients with ESKD

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

News All Time

Enhancing Perceived Behavioral Control May Improve Post-Transplant Medication Adherence Alex Hillenbrand

Perceived behavioral control emerged as a predictor of immunosuppression adherence after kidney transplantation, pointing to practical intervention targets.

Advanced CKD Increases Risk of ERCP Complications But Not PEP Alex Hillenbrand

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

Improved Glomerular Nephritis Diagnosis With Artificial Intelligence-Assisted Model Alex Hillenbrand

Artificial Intelligence-Assisted Model Can Automate Diagnosis of Glomerular Nephritis.

Utilizing Donor Recipient Characteristics To Improve Kidney Allograft Allocation Alex Hillenbrand

Post-transplant survival prediction algorithms can lower rates of donor discards.

High Neutrophil-To-Lymphocyte Ratio Linked to Early Renal Function Decline in IgAN Alex Hillenbrand

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.

ASN Kidney Week 2025 Preview: 5 Phase 3 Trials to Know Patrick Campbell

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Peritoneal Dialysis, Hemodialysis Yield Similar Survival Benefits for Kidney Failure Alex Hillenbrand

Meta-analysis finds peritoneal and hemodialysis offer similar survival in ESRD.

FDA Grants Orphan Drug Designation to ABBV-CLS-628 for ADPKD Alex Hillenbrand

ABBV-CLS-628, an anti–PAPP-A monoclonal antibody, earns Orphan Drug Designation, advancing through phase 2 testing for ADPKD.

5 Nephrology Headlines You Missed in October 2025 Alex Hillenbrand

October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs

FDA Approves Kygevvi, First Treatment for Thymidine Kinase 2 Deficiency Alex Hillenbrand

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

FINE-ONE: Finerenone Proves Benefit in Type 1 Diabetes and CKD Patrick Campbell

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Kidney Week 2025: ORIGIN 3 Sets the Stage for Atacicept in IgA Nephropathy Patrick Campbell

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

Anxiety, Depression Linked to Poor Sleep Quality in ESRD Patients on HD Alex Hillenbrand

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

PISCES: Fish Oil Slashes Cardiovascular Event Risk of Maintenance Dialysis Victoria Johnson

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

Almost All Adults With Hypertensive CKD Would Benefit From Lower Blood Pressure Target

Almost All Adults With Hypertensive CKD Would Benefit From Lower Blood Pressure Target

DUPLEX: Sparsentan Outperforms Irbesartan in Reaching Key Proteinuria Threshold in FSGS Victoria Johnson

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

Recommended News For You

combating racial discrimination in next-generation breast cancer screening.

New tumor therapy approach reduces costs and side effects while increasing accessibility

For relapsed or resistant DLBCL, odronextamab produced positive results.

New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

Recommended Articles For You

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training 

Hemophilia: Pathophysiology, Genetics, and Treatment Advances 

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care? 

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

2.

Why palliative care goes hand in hand with treatment for people with cancer: Q&A

3.

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

4.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

5.

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis

1.

Cancer Rates on the Rise: What Can We Do to Stop It?

2.

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook

3.

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment

4.

Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence

5.

Everything You Need to Know About RDW-CV: A Comprehensive Guide 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

4.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

5.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot